Roivant Sciences (ROIV) EBITDA Margin (2020 - 2025)
Roivant Sciences (ROIV) posted EBITDA Margin of 16207.46% for Q4 2025, up 16.85% on a QoQ basis from 19492.87% in Q3 2025, and down 1286375.0% year-over-year from N/an in Q4 2024.
Roivant Sciences (ROIV) EBITDA Margin (2020 - 2025) Analysis & Trends
Roivant Sciences' EBITDA Margin history runs 6 years deep, the most recent figure standing at 16207.46% for Q4 2025.
- Quarterly EBITDA Margin fell 1286375.0% year-over-year to 16207.46% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 7233.54% (down 1411263.0% YoY) and the FY2026 annual result came in at 6235.69%, down 278237.0% from the prior year.
- EBITDA Margin was 16207.46% for Q4 2025 at Roivant Sciences, up from 19492.87% in the prior quarter.
- Across five years, EBITDA Margin topped out at 21641.22% in Q4 2023 and bottomed at 19492.87% in Q3 2025.
- A 5-year average of 4492.46% and a median of 3343.71% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2023 — EBITDA Margin surged 2441716 bps — and 2024, when it plunged 2498493 bps.
- Roivant Sciences' EBITDA Margin stood at 2355.12% in 2021, then retreated by 18 bps to 2775.93% in 2022, then surged by 880 bps to 21641.22% in 2023, then plunged by 115 bps to 3343.71% in 2024, then tumbled by 385 bps to 16207.46% in 2025.
- Business Quant data shows ROIV's EBITDA Margin at 16207.46% in Q4 2025, 19492.87% in Q3 2025, and 13130.05% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Roivant Sciences | 24.35 Bn | 25.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -16,207.46% |
| Sep 30, 2025 | -19,492.87% |
| Jun 30, 2025 | -13,130.05% |
| Dec 31, 2024 | -3,343.71% |
| Sep 30, 2024 | -7,636.04% |
| Jun 30, 2024 | -1,279.54% |
| Dec 31, 2023 | 21,641.22% |
| Sep 30, 2023 | -5,863.24% |
| Jun 30, 2023 | -1,278.27% |
| Dec 31, 2022 | -2,775.93% |
| Sep 30, 2022 | -2,240.21% |
| Jun 30, 2022 | -6,536.44% |
| Dec 31, 2021 | -2,355.12% |
| Sep 30, 2021 | -4,893.32% |
| Jun 30, 2021 | -1,995.95% |
| Dec 31, 2020 | -4,505.57% |
| Sep 30, 2020 | -11,832.28% |
| Jun 30, 2020 | -7,262.25% |